Growth Metrics

Merck (MRK) Cash & Current Investments (2016 - 2025)

Merck (MRK) has disclosed Cash & Current Investments for 17 consecutive years, with $14.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 6.4% to $14.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $14.6 billion, a 6.4% increase, with the full-year FY2025 number at $14.6 billion, up 6.4% from a year prior.
  • Cash & Current Investments was $14.6 billion for Q4 2025 at Merck, down from $18.2 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $18.2 billion in Q3 2025 to a low of $5.6 billion in Q1 2024.
  • A 5-year average of $10.1 billion and a median of $9.2 billion in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: plummeted 46.23% in 2023, then soared 99.72% in 2024.
  • Merck's Cash & Current Investments stood at $8.1 billion in 2021, then skyrocketed by 62.94% to $13.2 billion in 2022, then tumbled by 46.23% to $7.1 billion in 2023, then skyrocketed by 92.99% to $13.7 billion in 2024, then grew by 6.4% to $14.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Cash & Current Investments are $14.6 billion (Q4 2025), $18.2 billion (Q3 2025), and $8.6 billion (Q2 2025).